Intellectual Property Rights: Abstract Book

Anju Goyal

ISBN 10: 6139851009 / ISBN 13: 9786139851003

Published by LAP LAMBERT Academic Publishing Jun 2018, 2018

About this Item

This item is printed on demand - Print on Demand Titel. Neuware -Pharmaceuticals have brought immense health benefits to developing countries, but one third of the world's population does not have access to existing essential drugs. The Commission on Health Research for Development (1990) showed that less than 10 per cent of global health research is directed towards diseases that afflict 90% of the world's population. IPRs in pharmaceuticals have two principal areas of impact which affect public health. First, there is the issue of access, where discussion focuses on the links between IPRs, exclusion of competitors and the availability and pricing of new medicines. Second, there is the issue of incentive innovation, where discussion focuses on the role of IPRs in motivating R&D and marketing of new drugs and the effect of IPRs on R&D expenditure and its allocation across diseases, countries and organizations.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 64 pp. Englisch.

Seller Inventory # 9786139851003

Bibliographic Details

• Title: Intellectual Property Rights: Abstract Book
• Publisher: LAP LAMBERT Academic Publishing Jun 2018
• Publication Date: 2018
• Language: English
• ISBN 10: 6139851009
• ISBN 13: 9786139851003
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 5D millimeters 220 millimeters width by 150 millimeters height by 5 millimeters depth
• Weight: 113 grams

About this title

Synopsis

Pharmaceuticals have brought immense health benefits to developing countries, but one third of the world’s population does not have access to existing essential drugs. The Commission on Health Research for Development (1990) showed that less than 10 per cent of global health research is directed towards diseases that afflict 90% of the world’s population. IPRs in pharmaceuticals have two principal areas of impact which affect public health. First, there is the issue of access, where discussion focuses on the links between IPRs, exclusion of competitors and the availability and pricing of new medicines. Second, there is the issue of incentive innovation, where discussion focuses on the role of IPRs in motivating R&D and marketing of new drugs and the effect of IPRs on R&D expenditure and its allocation across diseases, countries and organizations.